Tatiana N. Ermolaeva
Research Subjects
Tatiana N. Ermolaeva has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Konstantin A. Kokushkin
Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry
9 shared publications - A. D. Ermolaeva
Scientific and Practical Center for Clinical and Economic Analysis
8 shared publications - M. V. Davydovskaya
City Clinical Hospital No. 24
6 shared publications - Kseniya I. Polyakova
Scientific and Practical Center for Clinical and Economic Analysis of the Ministry of Health of the Moscow Region
5 shared publications - V. S. Krysanova
BIOTECH University
5 shared publications - Malwina Hołownia-Voloskova
Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw
4 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 234-243
Pharmacoeconomic evaluation of triple beclomethasone/glycopyrronium bromide/formoterol combination in the treatment of patients with moderate and severe chronic obstructive pulmonary disease
Objective : To conduct a pharmacoeconomic evaluation of the triple beclomethasone/formoterol/glycopyrronium fixed-dose combination (FDC) for the treatment of patients with moderate and severe chronic obstructive pulmonary disease (COPD) in healthcare institutions of the Moscow Region, Russia. Material and methods . A pharmacoepidemiological analysis was conducted using data from multiple levels of medical care for patients with COPD in the Moscow Region, including records data from the Territorial Fund for Compulsory Health Insurance (TFCHI) and data on subsidized drug provision. To characterize the frequency and structure of inpatient and outpatient care for COPD, a frequency analysis was performed. Direct costs of COPD pharmacotherapy were assessed, including expenditures associated with triple FDCs. In addition, a budget impact analysis was carried out to evaluate the provision of triple FDCs in a single delivery device. Results . During the analyzed period, 23,583 COPD patients received inpatient care and 7,314 received outpatient care, with total expenditures of 703,329,560 and 251,189,103 rubles, respectively. Analysis of subsidized drug provision showed that 757 patients (4.2% of all patients receiving COPD therapy) were treated with one of three triple FDCs: beclomethasone/glycopyrronium bromide/ formoterol, budesonide/glycopyrronium bromide/formoterol, or vilanterol/umeclidinium bromide/fluticasone furoate. Budget impact analysis demonstrated that two triple FDCs (budesonide/glycopyrronium bromide/formoterol and beclomethasone/glycopyrronium bromide/formoterol) were associated with identical costs: 2,763.20 rubles per month and 33,158.40 rubles per year. Treatment with the vilanterol/umeclidinium bromide/fluticasone furoate combination was associated with higher costs. Conclusion . Use of triple FDC of beclomethasone/glycopyrronium bromide/formoterol may help improve compliance to therapy among patients with COPD and is associated with lower costs for the Moscow Region healthcare system. This treatment approach is clinically and economically feasible.
- 19 August 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 19 (2) , 234-243
Open AccessPharmacoeconomic evaluation of triple beclomethasone/glycopyrronium bromide/formoterol combination in the treatment of patients with moderate and severe chronic obstructive pulmonary disease
Objective : To conduct a pharmacoeconomic evaluation of the triple beclomethasone/formoterol/glycopyrronium fixed-dose combination (FDC) for the treatment of patients with moderate and severe chronic obstructive pulmonary disease (COPD) in healthcare institutions of the Moscow Region, Russia. Material and methods . A pharmacoepidemiological analysis was conducted using data from multiple levels of medical care for patients with COPD in the Moscow Region, including records data from the Territorial Fund for Compulsory Health Insurance (TFCHI) and data on subsidized drug provision. To characterize the frequency and structure of inpatient and outpatient care for COPD, a frequency analysis was performed. Direct costs of COPD pharmacotherapy were assessed, including expenditures associated with triple FDCs. In addition, a budget impact analysis was carried out to evaluate the provision of triple FDCs in a single delivery device. Results . During the analyzed period, 23,583 COPD patients received inpatient care and 7,314 received outpatient care, with total expenditures of 703,329,560 and 251,189,103 rubles, respectively. Analysis of subsidized drug provision showed that 757 patients (4.2% of all patients receiving COPD therapy) were treated with one of three triple FDCs: beclomethasone/glycopyrronium bromide/ formoterol, budesonide/glycopyrronium bromide/formoterol, or vilanterol/umeclidinium bromide/fluticasone furoate. Budget impact analysis demonstrated that two triple FDCs (budesonide/glycopyrronium bromide/formoterol and beclomethasone/glycopyrronium bromide/formoterol) were associated with identical costs: 2,763.20 rubles per month and 33,158.40 rubles per year. Treatment with the vilanterol/umeclidinium bromide/fluticasone furoate combination was associated with higher costs. Conclusion . Use of triple FDC of beclomethasone/glycopyrronium bromide/formoterol may help improve compliance to therapy among patients with COPD and is associated with lower costs for the Moscow Region healthcare system. This treatment approach is clinically and economically feasible.
- 7 May 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 1 (19) , 5-14
Administration of tyrosyl-D-arginyl-phenylalanyl-glycine amide to manage postoperative pain in patients with type 2 diabetes mellitus and obesity: budget impact analysis
Objective : To evaluate the impact of administering tyrosyl-D-arginyl-phenylalanyl-glycine amide postoperatively to relieve pain in patients with type 2 diabetes mellitus (T2DM) and obesity on the compulsory health insurance system of Moscow Region. Material and methods . A pharmacoeconomic budget impact analysis covering a period of one year was conducted. The target population included T2DM and obesity patients aged over 18 years who received postoperative analgesic therapy (tyrosyl-D-arginyl-phenylalanylglycine amide, trimeperidine, or morphine). The regional budget impact analysis of drug therapy took into account the duration of analgesia, the incidence of complications and their treatment. A mathematical model was developed to calculate the direct medical costs of various postoperative analgesic regimens. The cost of pharmacotherapy and treatment of complications per patient during a course of medication was calculated. A sensitivity analysis of the obtained results was conducted. Results . A total of 1501 patients with T2DM and obesity underwent surgical treatment at the medical facilities of Moscow Region. The total sample of patients in the study was divided into three groups depending on the analgesic used. With the use of tyrosyl-D-arginylphenylalanyl-glycine amide, the incidence of complications in the analyzed patient population was almost four times lower compared to trimeperidine and morphine, and the cost of treating complications was almost three times lower. The total cost of treating one surgical patient experiencing a complication after the use of tyrosyl-D-arginyl-phenylalanyl-glycine amide amounted to 18,732.25 rubles, which is almost 1.3 times lower compared to other analgesic strategies. The budget impact analysis revealed the pharmacoeconomic feasibility of using tyrosyl-D-arginyl-phenylalanyl-glycine amide in postoperative analgesic therapy. Sensitivity analysis showed that the results were robust to changes in the initial parameters. Conclusion . Administration of tyrosyl-D-arginyl-phenylalanyl-glycine amide in the postoperative period leads to a proven reduction in the incidence of complications. This is a cost-effective approach to providing medical care to adult patients with T2DM and obesity.
- 7 May 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 1 (19) , 5-14
Administration of tyrosyl-D-arginyl-phenylalanyl-glycine amide to manage postoperative pain in patients with type 2 diabetes mellitus and obesity: budget impact analysis
Objective : To evaluate the impact of administering tyrosyl-D-arginyl-phenylalanyl-glycine amide postoperatively to relieve pain in patients with type 2 diabetes mellitus (T2DM) and obesity on the compulsory health insurance system of Moscow Region. Material and methods . A pharmacoeconomic budget impact analysis covering a period of one year was conducted. The target population included T2DM and obesity patients aged over 18 years who received postoperative analgesic therapy (tyrosyl-D-arginyl-phenylalanylglycine amide, trimeperidine, or morphine). The regional budget impact analysis of drug therapy took into account the duration of analgesia, the incidence of complications and their treatment. A mathematical model was developed to calculate the direct medical costs of various postoperative analgesic regimens. The cost of pharmacotherapy and treatment of complications per patient during a course of medication was calculated. A sensitivity analysis of the obtained results was conducted. Results . A total of 1501 patients with T2DM and obesity underwent surgical treatment at the medical facilities of Moscow Region. The total sample of patients in the study was divided into three groups depending on the analgesic used. With the use of tyrosyl-D-arginylphenylalanyl-glycine amide, the incidence of complications in the analyzed patient population was almost four times lower compared to trimeperidine and morphine, and the cost of treating complications was almost three times lower. The total cost of treating one surgical patient experiencing a complication after the use of tyrosyl-D-arginyl-phenylalanyl-glycine amide amounted to 18,732.25 rubles, which is almost 1.3 times lower compared to other analgesic strategies. The budget impact analysis revealed the pharmacoeconomic feasibility of using tyrosyl-D-arginyl-phenylalanyl-glycine amide in postoperative analgesic therapy. Sensitivity analysis showed that the results were robust to changes in the initial parameters. Conclusion . Administration of tyrosyl-D-arginyl-phenylalanyl-glycine amide in the postoperative period leads to a proven reduction in the incidence of complications. This is a cost-effective approach to providing medical care to adult patients with T2DM and obesity.
- 7 July 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (6) , 23-33
Pharmacoeconomic Aspects of Using New Generation Drugs Of PCSK-9 Inhibitor and Acting on The Effect of Ribonucleic Acid Interference Classes in The Treatment of Patients With Hypercholesterolemia at High Risk of Cardiovascular Events
Aim Clinical and economic analysis of the feasibility of using new-generation drugs of the PCSK-9 inhibitor class (alirocumab and evolocumab) and the drugs that utilize in their action the effect of ribonucleic acid interference (inclisiran) in the treatment of patients with a high risk of cardiovascular events in medical organizations of the Moscow Region (MR). Material and methods Based on statistical and literature data on morbidity, as well as data from real-life practice about using alirocumab, evolocumab, and inclisiran in medical organizations of the MR, populations of patients with hypercholesterolemia and cardiovascular pathology were identified in that region. Two analytical models were developed that include the structure and number of patients receiving a combination therapy (high-dose statins + ezetimibe + alirocumab/evolocumab/inclisiran). To estimate the economic feasibility of the treatment with innovative drugs, direct medical costs were calculated for various therapeutic regimens. The cost of pharmacotherapy was calculated per patient per one-year course. A budget impact analysis (BIA) and a sensitivity analysis of the results were performed. The modeling period of the study was 3 years. Results The number of patients in different populations receiving the combination therapy will be 12,228 and 895 people in the first year, and 12,973 and 950 people in the third year, taking into account the determined increase in the patient number. The total costs of treating one patient with hypercholesterolemia and cardiovascular diseases during the first year of therapy with inclisiran are 23.31 and 27.66% lower than with evolocumab and alirocumab, respectively. The BIA revealed a slight increase in the total cost of treating patients in each population (by 1.39 and 1.69% compared to 2024). The increase in the regional budget will be related only with the annual increase in the number of patients with hypercholesterolemia. The sensitivity analysis showed the robustness of the results to changes in the initial parameter values. Conclusion The treatment of patients with dyslipidemia and high risk of cardiovascular events with alirocumab/evolocumab/inclisiran as part of the combination therapy is an economically justified strategy in the settings of the regional healthcare system.
- 7 July 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (6) , 23-33
Pharmacoeconomic Aspects of Using New Generation Drugs Of PCSK-9 Inhibitor and Acting on The Effect of Ribonucleic Acid Interference Classes in The Treatment of Patients With Hypercholesterolemia at High Risk of Cardiovascular Events
Aim Clinical and economic analysis of the feasibility of using new-generation drugs of the PCSK-9 inhibitor class (alirocumab and evolocumab) and the drugs that utilize in their action the effect of ribonucleic acid interference (inclisiran) in the treatment of patients with a high risk of cardiovascular events in medical organizations of the Moscow Region (MR). Material and methods Based on statistical and literature data on morbidity, as well as data from real-life practice about using alirocumab, evolocumab, and inclisiran in medical organizations of the MR, populations of patients with hypercholesterolemia and cardiovascular pathology were identified in that region. Two analytical models were developed that include the structure and number of patients receiving a combination therapy (high-dose statins + ezetimibe + alirocumab/evolocumab/inclisiran). To estimate the economic feasibility of the treatment with innovative drugs, direct medical costs were calculated for various therapeutic regimens. The cost of pharmacotherapy was calculated per patient per one-year course. A budget impact analysis (BIA) and a sensitivity analysis of the results were performed. The modeling period of the study was 3 years. Results The number of patients in different populations receiving the combination therapy will be 12,228 and 895 people in the first year, and 12,973 and 950 people in the third year, taking into account the determined increase in the patient number. The total costs of treating one patient with hypercholesterolemia and cardiovascular diseases during the first year of therapy with inclisiran are 23.31 and 27.66% lower than with evolocumab and alirocumab, respectively. The BIA revealed a slight increase in the total cost of treating patients in each population (by 1.39 and 1.69% compared to 2024). The increase in the regional budget will be related only with the annual increase in the number of patients with hypercholesterolemia. The sensitivity analysis showed the robustness of the results to changes in the initial parameter values. Conclusion The treatment of patients with dyslipidemia and high risk of cardiovascular events with alirocumab/evolocumab/inclisiran as part of the combination therapy is an economically justified strategy in the settings of the regional healthcare system.
- 17 March 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (1)
Clinical and economic effectiveness of thrombopoietin receptor agonists in the treatment of primary immune thrombocytopenia in the Moscow region
Objective. To perfom cost-effectiveness and budget impact analysis (BIA) of thrombopoietin receptor agonists (romiplostim, eltrombopag and avatrombopag) in the treatment of adults with idiopathic thrombocytopenic purpura (ITP) in hospitals of the Moscow region (MR). Material and methods. The effectiveness criterion in cost-effectiveness analysis was the patient’s response to therapy. We prepared a model of providing care to adults with ITP. This model included assessment of economic and clinical effectiveness of various treatment strategies, as well as long-term prediction of budget expenditures for MR healthcare system following changes in appropriate practice. The study was conducted from the perspective of regional healthcare system. Therefore, we analyzed only direct medical costs for medications, drug administration, therapy monitoring, «rescue therapy» and treatment of major bleeding. Results. Cost-effectiveness analysis established the advantage of avatrombopag (981 305.46 rubles) over eltrombopag (1 030 500.81 rubles) and romiplostim (1 918 933.40 rubles) The difference in cost effectiveness of avatrombopag was 1 215.951.77 and 10 726 613.25 rubles, respectively. BIA showed that pharmacotherapy with thrombopoietin receptor agonists will increase total costs by 22.47% by 2025 considering annual increase in the number of patients with ITP and changes in proportions of the analyzed drugs. Treatment strategy for avatrombopag will be economically feasible throughout the entire period. Conclusion. Avatrombopag therapy is a clinically and economically justified strategy for medical care in adults with ITP in the MR.
- 17 March 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (1)
Clinical and economic effectiveness of thrombopoietin receptor agonists in the treatment of primary immune thrombocytopenia in the Moscow region
Objective. To perfom cost-effectiveness and budget impact analysis (BIA) of thrombopoietin receptor agonists (romiplostim, eltrombopag and avatrombopag) in the treatment of adults with idiopathic thrombocytopenic purpura (ITP) in hospitals of the Moscow region (MR). Material and methods. The effectiveness criterion in cost-effectiveness analysis was the patient’s response to therapy. We prepared a model of providing care to adults with ITP. This model included assessment of economic and clinical effectiveness of various treatment strategies, as well as long-term prediction of budget expenditures for MR healthcare system following changes in appropriate practice. The study was conducted from the perspective of regional healthcare system. Therefore, we analyzed only direct medical costs for medications, drug administration, therapy monitoring, «rescue therapy» and treatment of major bleeding. Results. Cost-effectiveness analysis established the advantage of avatrombopag (981 305.46 rubles) over eltrombopag (1 030 500.81 rubles) and romiplostim (1 918 933.40 rubles) The difference in cost effectiveness of avatrombopag was 1 215.951.77 and 10 726 613.25 rubles, respectively. BIA showed that pharmacotherapy with thrombopoietin receptor agonists will increase total costs by 22.47% by 2025 considering annual increase in the number of patients with ITP and changes in proportions of the analyzed drugs. Treatment strategy for avatrombopag will be economically feasible throughout the entire period. Conclusion. Avatrombopag therapy is a clinically and economically justified strategy for medical care in adults with ITP in the MR.
- Open Access
- 9 November 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (3) , 387-399
Clinical and economic assessment of feasibility of using quadritherapy in patients with reduced ejection fraction chronic heart failure in medical organizations of the Moscow Region
Objective: assessment of feasibility of using four-component drug therapy for patients with chronic heart failure with reduced ejection fraction (CHFrEF) in medical organizations of the Moscow Region (MR).Material and methods. Clinical and economic analysis of combined standard therapy with angiotensin-converting enzyme inhibitors, beta-blockers, and mineralocorticoid-receptor antagonists in combination with dapagliflozin (a sodium-glucose cotransporter 2) in the treatment of patients with CHFrEF was carried out. The effectiveness criteria were the number of prevented cardiovascular (CV) deaths and the percentage of the contribution to the achievement of the target indicator to reduce mortality from circulatory diseases within the framework of the regional program “Health care development”. In order to determine the economic feasibility of quadritherapy, direct medical costs for the implemented technology were calculated, the cost of one prevented CV death was determined based on the values of the number needed to treat (NNT) indicator. Budget impact analysis was performed which allowed to build two analytical models. Results. It was shown that the use of quadritherapy can significantly contribute to achieving the target indicator by additionally preventing 512 CV deaths by 2024, which will make it possible to fulfill up to 74.74% of the indicator set by the MR state program “Health care of the Moscow Region” (451.4 persons per 100 thousand population). Using quadruple therapy in 1000 target patients during the first year will prevent 11 CV deaths (NNT 90 persons). The cost of one prevented CV death was 3.860 million rubles. The budget impact analysis made it possible to determine that when CHF patients switch from standard treatment regimens to quadritherapy, including in combination with a drug of the angiotensin/neprilysin receptor inhibitor group (valsartan + sacubitril), this will entail an increase in healthcare system budget costs by 18.8%.Conclusion. The results demonstrate that the standard therapy in combination with the innovative drug dapagliflozin leads to a proven reduction in mortality from circulatory diseases. This technology is a cost-effective approach to organizing medical care for adult patients with CHFrEF on the MR territory.
- 9 November 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (3) , 387-399
Open AccessClinical and economic assessment of feasibility of using quadritherapy in patients with reduced ejection fraction chronic heart failure in medical organizations of the Moscow Region
Objective: assessment of feasibility of using four-component drug therapy for patients with chronic heart failure with reduced ejection fraction (CHFrEF) in medical organizations of the Moscow Region (MR).Material and methods. Clinical and economic analysis of combined standard therapy with angiotensin-converting enzyme inhibitors, beta-blockers, and mineralocorticoid-receptor antagonists in combination with dapagliflozin (a sodium-glucose cotransporter 2) in the treatment of patients with CHFrEF was carried out. The effectiveness criteria were the number of prevented cardiovascular (CV) deaths and the percentage of the contribution to the achievement of the target indicator to reduce mortality from circulatory diseases within the framework of the regional program “Health care development”. In order to determine the economic feasibility of quadritherapy, direct medical costs for the implemented technology were calculated, the cost of one prevented CV death was determined based on the values of the number needed to treat (NNT) indicator. Budget impact analysis was performed which allowed to build two analytical models. Results. It was shown that the use of quadritherapy can significantly contribute to achieving the target indicator by additionally preventing 512 CV deaths by 2024, which will make it possible to fulfill up to 74.74% of the indicator set by the MR state program “Health care of the Moscow Region” (451.4 persons per 100 thousand population). Using quadruple therapy in 1000 target patients during the first year will prevent 11 CV deaths (NNT 90 persons). The cost of one prevented CV death was 3.860 million rubles. The budget impact analysis made it possible to determine that when CHF patients switch from standard treatment regimens to quadritherapy, including in combination with a drug of the angiotensin/neprilysin receptor inhibitor group (valsartan + sacubitril), this will entail an increase in healthcare system budget costs by 18.8%.Conclusion. The results demonstrate that the standard therapy in combination with the innovative drug dapagliflozin leads to a proven reduction in mortality from circulatory diseases. This technology is a cost-effective approach to organizing medical care for adult patients with CHFrEF on the MR territory.
- Open Access
- 19 August 2021
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 9 (3) , 235-248-248
ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES
A certain success in the treatment of bronchial asthma is associated with the introduction of monoclonal antibodies into the treatment process. They made it possible to improve the control of the disease. A number of original genetically engineered biological drugs, such as benralizumab, reslizumab, dupilumab, mepolizumab and omalizumab, are currently registered in Russia. In 2020, this list was supplemented by the first Russian biosimilar drug omalizumab – Genolar® (JSC Generium, Russia). High rates of the development of modern medicine are closely related to the use of biosimilars. The prescription of biosimilars today often makes it possible to provide a larger number of patients with modern drugs at lower costs.The aim of the study was a comprehensive pharmacoeconomic assessment of the application of the domestic biosimilar drug omalizumab in the treatment of patients suffering from moderate and severe atopic bronchial asthma.Materials and methods. At the first stage, an information search in the available databases (Cochrane Library, MedLine, Embase, eLIBRARY) was carried out. According to the results obtained, a meta-analysis (Agache I. et al.) was found out; within its framework, the efficacy and safety of the use of several monoclonal antibodies was assessed. Dupilumab was chosen as the reference drug. Pharmacoeconomic analyses were carried out using a “Cost-Minimization Analysis” (CMA) and a “Budget Impact Analysis” (BIA). Taking into account various options of bronchial asthma, the developed algorithm for providing medical care to adult patients with atopic asthma made it possible to assess the costs, including direct medical and indirect costs.Results. The cost analysis demonstrated the advantage of using the Russian biosimilar omalizumab in patients with atopic asthma compared to dupilumab due to financial savings of up to 40%. The Budget Impact Analysis showed that the use of the domestic biosimilar omalizumab, even taking into account the annual increase in the number of patients (8%), will save up to 109,641,409.64 rubles (or 3%) compared to the current practice.Conclusion. The use of the domestic biosimilar omalizumab in patients with moderate to severe atopic bronchial asthma is a clinically effective and economically justified approach to organizing medical care for adult patients in Russia.
- 19 August 2021
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 9 (3) , 235-248-248
Open AccessECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES
A certain success in the treatment of bronchial asthma is associated with the introduction of monoclonal antibodies into the treatment process. They made it possible to improve the control of the disease. A number of original genetically engineered biological drugs, such as benralizumab, reslizumab, dupilumab, mepolizumab and omalizumab, are currently registered in Russia. In 2020, this list was supplemented by the first Russian biosimilar drug omalizumab – Genolar® (JSC Generium, Russia). High rates of the development of modern medicine are closely related to the use of biosimilars. The prescription of biosimilars today often makes it possible to provide a larger number of patients with modern drugs at lower costs.The aim of the study was a comprehensive pharmacoeconomic assessment of the application of the domestic biosimilar drug omalizumab in the treatment of patients suffering from moderate and severe atopic bronchial asthma.Materials and methods. At the first stage, an information search in the available databases (Cochrane Library, MedLine, Embase, eLIBRARY) was carried out. According to the results obtained, a meta-analysis (Agache I. et al.) was found out; within its framework, the efficacy and safety of the use of several monoclonal antibodies was assessed. Dupilumab was chosen as the reference drug. Pharmacoeconomic analyses were carried out using a “Cost-Minimization Analysis” (CMA) and a “Budget Impact Analysis” (BIA). Taking into account various options of bronchial asthma, the developed algorithm for providing medical care to adult patients with atopic asthma made it possible to assess the costs, including direct medical and indirect costs.Results. The cost analysis demonstrated the advantage of using the Russian biosimilar omalizumab in patients with atopic asthma compared to dupilumab due to financial savings of up to 40%. The Budget Impact Analysis showed that the use of the domestic biosimilar omalizumab, even taking into account the annual increase in the number of patients (8%), will save up to 109,641,409.64 rubles (or 3%) compared to the current practice.Conclusion. The use of the domestic biosimilar omalizumab in patients with moderate to severe atopic bronchial asthma is a clinically effective and economically justified approach to organizing medical care for adult patients in Russia.
- Open Access
- 27 July 2021
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 14 (2) , 151-166
Medical care payment improvement within diagnosis-related groups of patients with severe asthma requiring biologic disease-modifying drugs by regional adaptation mechanism in the Moscow Region
Objective: scientific rationale of changing approaches to medical care payment for hospitalization of patients suffering from severe asthma (SA) that require the prescription of biologic disease-modifying drugs (bDMDs) within the constraints of diagnosis-related groups (DRGs) on the level of the Moscow Region.Material and methods. For the federal model regional adaptation, the authors used the mechanism of subgroups selection in the structure of basic DRG No. 336 st36.003 and No. 139 ds36.004 “Treatment with biologic disease-modifying drugs and selective immunosuppressants” in the round-the-clock (RH) and day-time hospital (DH). Budget impact analysis (BIA) was performed to provide scientific and economic feasibility for the improvement of medical care payment for bDMDs proscribed to patients with SA within DRG at the level of the Moscow Region.Results. The analysis of cost of drug therapy and medical services per 1 case of hospitalization of patients with SA, that required bDMDs therapy, considering the classification criterion (international nonproprietary name of drugs and drug therapy regimens), showed 10 subgroups in DRG No. 336 st36.003 (level 1) and 9 subgroups in DRG No. 139 ds36.004. Expert estimates on the rate of hospitalizations and drug dosage regimen indicated for patients with SA were used to calculate the relative cost weights (CW). The highest CW was observed in the subgroup that received benralizumab in RH (CW=7.46) and in DH (CW=12.08) conditions. BIA demonstrated 110,103,901.53 rubles (or 31%) budget savings for the health care system of the Moscow Region.Conclusion. The implementation of the adapted DRG federal model in the conditions of the health care system of Moscow Region is an economically feasible approach to the organization of the inpatient medical care provided to patients with SA needing bDMDs prescription.
- 27 July 2021
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 14 (2) , 151-166
Open AccessMedical care payment improvement within diagnosis-related groups of patients with severe asthma requiring biologic disease-modifying drugs by regional adaptation mechanism in the Moscow Region
Objective: scientific rationale of changing approaches to medical care payment for hospitalization of patients suffering from severe asthma (SA) that require the prescription of biologic disease-modifying drugs (bDMDs) within the constraints of diagnosis-related groups (DRGs) on the level of the Moscow Region.Material and methods. For the federal model regional adaptation, the authors used the mechanism of subgroups selection in the structure of basic DRG No. 336 st36.003 and No. 139 ds36.004 “Treatment with biologic disease-modifying drugs and selective immunosuppressants” in the round-the-clock (RH) and day-time hospital (DH). Budget impact analysis (BIA) was performed to provide scientific and economic feasibility for the improvement of medical care payment for bDMDs proscribed to patients with SA within DRG at the level of the Moscow Region.Results. The analysis of cost of drug therapy and medical services per 1 case of hospitalization of patients with SA, that required bDMDs therapy, considering the classification criterion (international nonproprietary name of drugs and drug therapy regimens), showed 10 subgroups in DRG No. 336 st36.003 (level 1) and 9 subgroups in DRG No. 139 ds36.004. Expert estimates on the rate of hospitalizations and drug dosage regimen indicated for patients with SA were used to calculate the relative cost weights (CW). The highest CW was observed in the subgroup that received benralizumab in RH (CW=7.46) and in DH (CW=12.08) conditions. BIA demonstrated 110,103,901.53 rubles (or 31%) budget savings for the health care system of the Moscow Region.Conclusion. The implementation of the adapted DRG federal model in the conditions of the health care system of Moscow Region is an economically feasible approach to the organization of the inpatient medical care provided to patients with SA needing bDMDs prescription.
- 11 May 2021
- Published by Federal Scientific Center for Hygiene F.F.Erisman in Health Care of the Russian Federation
- Vol. 65 (2) , 125-134
Methodological outlines for assessing the costs of cancer patients care
Introduction. The planning of funding in the public health system and specifically in cancer care remains a challenge for the medical community. Some issues of cancer cost analysis are still not entirely resolved. Aims. To review the options for analysis of direct cancer costs based on registered follow-up data. Methods. The targeting and consensus search methodology was applied to collect the relevant papers from PubMed, Cochrane, E-library (RSCI). Results and Discussion. The following options have been identified: 1) using incidence data; 2) using prevalence data; 3) system net and total costs approach; 4) phase approach; 5) cost estimation using censored data. The incidence costs are related to the time of diagnosis. The prevalence costs represent the costs over a fixed calendar period. The net costs can be calculated by subtracting the mean costs across non-cancer patients from the total mean costs across comparable cancer patients. Total costs are defined as the summated costs for cancer patients regardless of whether they are associated with cancer or not. Phase analysis is a variant of estimates based on morbidity data and includes identifying specific periods from the diagnosis when the costs significantly change. Cost estimation using censored data provides for the application of mathematical modeling methods. Conclusion. The availability of combined cost analysis methods makes it possible to obtain a comprehensive economic assessment for cancer treatment approaches.
- 11 May 2021
- Published by Federal Scientific Center for Hygiene F.F.Erisman in Health Care of the Russian Federation
- Vol. 65 (2) , 125-134
Methodological outlines for assessing the costs of cancer patients care
Introduction. The planning of funding in the public health system and specifically in cancer care remains a challenge for the medical community. Some issues of cancer cost analysis are still not entirely resolved. Aims. To review the options for analysis of direct cancer costs based on registered follow-up data. Methods. The targeting and consensus search methodology was applied to collect the relevant papers from PubMed, Cochrane, E-library (RSCI). Results and Discussion. The following options have been identified: 1) using incidence data; 2) using prevalence data; 3) system net and total costs approach; 4) phase approach; 5) cost estimation using censored data. The incidence costs are related to the time of diagnosis. The prevalence costs represent the costs over a fixed calendar period. The net costs can be calculated by subtracting the mean costs across non-cancer patients from the total mean costs across comparable cancer patients. Total costs are defined as the summated costs for cancer patients regardless of whether they are associated with cancer or not. Phase analysis is a variant of estimates based on morbidity data and includes identifying specific periods from the diagnosis when the costs significantly change. Cost estimation using censored data provides for the application of mathematical modeling methods. Conclusion. The availability of combined cost analysis methods makes it possible to obtain a comprehensive economic assessment for cancer treatment approaches.
- Open Access
- 18 November 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (3) , 291-303
Economic burden of systemic sclerosis: systematic review
Background. Systemic sclerosis (SSc) is a severe orphan disease, one of the systemic pathologies of connective tissue. This disease has a significant negative impact on the patient’s quality of life and has a high mortality rate. Treatment of its various complications imposes a great financial burden on the healthcare system. The difficulties of daily functioning and social adaptation and the overall burden of SSc for patients, as well as their caregivers, also contribute to the economic component of the disease.Aim. To assess the social and economic burden of SSc.Materials and methods. A systematic review was conducted according to the PRISMA guidelines using predefined PICO(S) criteria. The search was carried out in December 2019 using the MeSH terms in the Embase, MEDLINE / PubMed, Cochrane library databases. The publication date range was 10 years. To identify Russian-language studies, an additional search was conducted in eLIBRARY.ru and the Internet network. The evidence levels of the included studies were determined.Results. A total of 934 studies were identified from all databases; 53 publications were selected for eligibility; 9 of which were included in the final review. There were no studies identified to assess the burden of SSc in Russia, so the evaluations were based on foreign studies. The estimates of the annual direct costs per patient with SSc for the past decade were almost similar in different countries: 5 038 Canadian dollars in Canada, 11 607 Australian dollars in Australia, 17 365-22 016 US dollars in the USA, and 1 413-17 300 Euros in Europe (an average of about 8 000 euros). The cost structure was dominated by direct medical costs for hospitalization and drug therapy and indirect costs were mostly associated with the loss of productivity and early retirement. The costs associated with the diffuse cutaneous form of SSc were statistically higher if compared to the costs for the limited form of the disease. Among the clinical manifestations of the disease, lung lesions and gastrointestinal problems made the largest contribution to the economic burden.Conclusion. SSc is associated with significant healthcare resource use compared to the general population. The economic burden of SS has grown significantly in recent years, and this trend is global. At the same time, it is difficult to evaluate the disease costs in Russia due to a lack of information on the patient population.
- 18 November 2020
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 13 (3) , 291-303
Open AccessEconomic burden of systemic sclerosis: systematic review
Background. Systemic sclerosis (SSc) is a severe orphan disease, one of the systemic pathologies of connective tissue. This disease has a significant negative impact on the patient’s quality of life and has a high mortality rate. Treatment of its various complications imposes a great financial burden on the healthcare system. The difficulties of daily functioning and social adaptation and the overall burden of SSc for patients, as well as their caregivers, also contribute to the economic component of the disease.Aim. To assess the social and economic burden of SSc.Materials and methods. A systematic review was conducted according to the PRISMA guidelines using predefined PICO(S) criteria. The search was carried out in December 2019 using the MeSH terms in the Embase, MEDLINE / PubMed, Cochrane library databases. The publication date range was 10 years. To identify Russian-language studies, an additional search was conducted in eLIBRARY.ru and the Internet network. The evidence levels of the included studies were determined.Results. A total of 934 studies were identified from all databases; 53 publications were selected for eligibility; 9 of which were included in the final review. There were no studies identified to assess the burden of SSc in Russia, so the evaluations were based on foreign studies. The estimates of the annual direct costs per patient with SSc for the past decade were almost similar in different countries: 5 038 Canadian dollars in Canada, 11 607 Australian dollars in Australia, 17 365-22 016 US dollars in the USA, and 1 413-17 300 Euros in Europe (an average of about 8 000 euros). The cost structure was dominated by direct medical costs for hospitalization and drug therapy and indirect costs were mostly associated with the loss of productivity and early retirement. The costs associated with the diffuse cutaneous form of SSc were statistically higher if compared to the costs for the limited form of the disease. Among the clinical manifestations of the disease, lung lesions and gastrointestinal problems made the largest contribution to the economic burden.Conclusion. SSc is associated with significant healthcare resource use compared to the general population. The economic burden of SS has grown significantly in recent years, and this trend is global. At the same time, it is difficult to evaluate the disease costs in Russia due to a lack of information on the patient population.
- Open Access
- 6 November 2020
- Published by Federal Scientific Center for Hygiene F.F.Erisman in Health Care of the Russian Federation
- Vol. 64 (5) , 258-263
Pharmacoeconomic analysis of the management of glaucoma with prostaglandin analogs
Introduction. Prevention and treatment of glaucoma, which threatens the development of blindness, is one of the most important medical and social problems facing modern society in the era of value-based health care. However, against the background of a wide selection of prostaglandin-F2α analogs, which have an approximately similar level of decrease in ophthalmotonus, a clinical and economic argumentation is required for the approach when forming a budget for drug treatment of glaucoma. The aim of the study. To assess the burden on the health budget of the city of Moscow when using the fluorinated prostaglandin-F2α analog as compared to other prostaglandin-F2α analogs for the treatment of adult patients with primary open-angle glaucoma. Material and methods. There was studied data on the population of patients with a diagnosis of «glaucoma» receiving medication from the budgetary funds of the city of Moscow. The direct medical costs of healthcare in Moscow were calculated for preparations of prostaglandin-F2α analogs for the treatment of adult patients with primary open-angle glaucoma in various clinical options for 5 years. Results. The use of the fluorinated prostaglandin-F2α analog drug Tafluprost in patients with primary open-angle glaucoma is economically justified, while budget savings in the 5-year horizon amounted to 196,777,224.60 rubles, 12,295,378.28 rubles in the baseline scenario (default appointment). and 116 084 865.02 rubles, and in alternative scenarios (appointment for adverse events on Latanoprost) - 125 113 646.70 rubles, 43 942 565.04 rubles. and 89,609,415.58 rubles, respectively. Conclusion. The inclusion of the drug Tafluprost in the drug supply programs of the Moscow healthcare system will increase the efficiency of the use of financial resources and increase the availability of drug supply.
- 6 November 2020
- Published by Federal Scientific Center for Hygiene F.F.Erisman in Health Care of the Russian Federation
- Vol. 64 (5) , 258-263
Open AccessPharmacoeconomic analysis of the management of glaucoma with prostaglandin analogs
Introduction. Prevention and treatment of glaucoma, which threatens the development of blindness, is one of the most important medical and social problems facing modern society in the era of value-based health care. However, against the background of a wide selection of prostaglandin-F2α analogs, which have an approximately similar level of decrease in ophthalmotonus, a clinical and economic argumentation is required for the approach when forming a budget for drug treatment of glaucoma. The aim of the study. To assess the burden on the health budget of the city of Moscow when using the fluorinated prostaglandin-F2α analog as compared to other prostaglandin-F2α analogs for the treatment of adult patients with primary open-angle glaucoma. Material and methods. There was studied data on the population of patients with a diagnosis of «glaucoma» receiving medication from the budgetary funds of the city of Moscow. The direct medical costs of healthcare in Moscow were calculated for preparations of prostaglandin-F2α analogs for the treatment of adult patients with primary open-angle glaucoma in various clinical options for 5 years. Results. The use of the fluorinated prostaglandin-F2α analog drug Tafluprost in patients with primary open-angle glaucoma is economically justified, while budget savings in the 5-year horizon amounted to 196,777,224.60 rubles, 12,295,378.28 rubles in the baseline scenario (default appointment). and 116 084 865.02 rubles, and in alternative scenarios (appointment for adverse events on Latanoprost) - 125 113 646.70 rubles, 43 942 565.04 rubles. and 89,609,415.58 rubles, respectively. Conclusion. The inclusion of the drug Tafluprost in the drug supply programs of the Moscow healthcare system will increase the efficiency of the use of financial resources and increase the availability of drug supply.